
Please try another search
Name | Title | Since | Until |
---|---|---|---|
Scott Wilkin | - | 2024 | Now |
Biography | Scott is the Head of the Global Intrinsic Value Equity team and co-PM for our Global equity portfolios. He is also Director of Research (DOR); responsible for managing the 13-member analyst team and driving research quality standards across the Global Intrinsic Value platform. In 2012, Scott was promoted to the position of DOR for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the health care analyst team. His responsibilities included fundamental company and industry-level research. | ||
Charlotte Harris | - | 2024 | Now |
Matthew Konosky | - | 2017 | Now |
Biography | Matthew Konosky is the Lead Healthcare Portfolio Manager and a Senior Investment Analyst on UBS Asset Management's US Intrinsic Value Equity Team. In his portfolio manager role, Matthew is Lead Portfolio Manager for the Global Healthcare Lux Fund as well as Deputy Portfolio Manager for the Global Biotech Lux Fund. Analyst responsibilities include fundamental company and industry-level research and development of company earnings models for the global pharmaceuticals and health care services sectors. Prior to joining the firm in 2006, Matthew worked as health care services analyst at Sanford C. Bernstein in New York and as a senior consultant at Mars & Co. serving several Fortune 500 health care clients. Matthew has also served as a member of the MIT Educational Counsel since 1997. | ||
Sara Cotter | - | 2022 | 2024 |
Florian Töpfl | - | 2019 | 2023 |
Nathalie Lötscher Petrus | - | 2006 | 2022 |
Christian Suter | - | 2012 | 2019 |
Biography | Christian Suter is an Equity Specialist, based in Zurich. He works closely together with the equity investment teams of UBS Asset Management and is responsible for presenting equity strategies to clients, prospects and consultants, primarily focusing on our Swiss, Biotech and Healthcare strategies. Further Christian is the deputy portfolio manager for the Swiss High Dividend and Swiss Income strategies and acts as a member of the portfolio construction team for Swiss Equities. In addition Christian covers Swiss Small and Mid Cap Industrials as well as the Biotech sector as an analyst. In 2009, Christian joined UBS within the graduate training program for the second time, after he made his first experiences at UBS before University in UBS WM&SB and UBS Investment Bank. | ||
André Leue | - | 2016 | 2017 |
Biography | André Leue is a Senior Investment Analyst. He is responsible for industry and company research, qualitative assessment and quantitative financial modelling within the Healthcare sector. André is Deputy Portfolio Manager for the UBS (Lux) Equity Fund – Biotech. André joined UBS Asset Management in February 2010. Prior to this he was head of the Healthcare team at DEKA Investment. As the Lead Portfolio Manager he was responsible for a Healthcare fund and a Biotech fund with combined assets under management of around USD 2bn. Other previous roles included senior financial analyst at Sal. Oppenheim Jr. & Cie and financial auditor at KPMG International. | ||
Scott Wilkin | - | 2016 | 2016 |
Biography | Scott Wilkin was appointed co-head of the enlarged Global Equity team in 2025, following the merger of the Global Equity and Global Value teams. He is also Director of Research. He acts as Lead PM on a number of strategies while being overall responsible for driving and maintaining excellent research standards across the team. Scott was appointed Head of Global Equity in 2016, having proven himself as one of the strongest investors across Active equities in various research roles, culminating in being Director of Research in the US. In 2012, Scott was promoted to the position of Director of Research (DOR) for the US Intrinsic Value equity team. In this role, Scott managed a team of six sector-based analysts and lead company and industry-level research. Scott was also the lead portfolio manager of the Intrinsic Value equity team's Global Healthcare and UBS Healthcare Long/Short strategies. Prior to being named DOR and portfolio manager, Scott was a Senior Investment Analyst and Sector Head for the Healthcare analyst team. His responsibilities included fundamental company and industry-level research. Before joining the firm in 2003, Scott spent seven years as a securities analyst covering the medical device industry, most recently as a managing director at SG Cowen. Scott started his career serving in various business development, strategic planning and market research roles in the specialty pharmaceutical and diagnostic industries. Scott is a member of the Investments Committee to the board of the American Diabetes Association (ADA). | ||
Sara Cotter | - | 2015 | 2016 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review